Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics

American Journal of Hypertension

Volumn 22, Issue 5, 2009, Pages 545-551

  Bozkurt, Özlem ^a   De Boer, Anthonius ^a   Grobbee, Diederik E ^b   De Leeuw, Peter W ^c   Kroon, Abraham A ^c   Schiffers, Paul ^c   Klungel, Olaf H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLOROTHIAZIDE; CHLORTALIDONE; CLOPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPITIZIDE; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MEFRUSIDE; SODIUM CHLORIDE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM EXCRETION;

AGED; ANGIOTENSINOGEN; CALMODULIN-BINDING PROTEINS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RISK; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 67349103845     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.38     Document Type: Article

References (25)

1. Messerli, FH, Grossman E, Goldbourt U. Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 2001; 14:S12-S16.
2. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 2447-2452.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207. Erratum in: Lancet. 2007; 369:1518.
4. Gorden P, Sherman BM, Simopoulos AP. Glucose intolerance with hypokalemia: an increased proportion of circulating proinsulin-like component. J Clin Endocrinol Metab 1972; 34:235-240.
5. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980; 29:498-502.
6. Rapoport MI, Hurd HF. Thiazide-induced glucose intolerance treated with potassium. Arch Intern Med 1964; 113:405-408.
7. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219-224.
8. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright JT Jr; Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension2008; 52:30-36.
9. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Stricker BH, Kroon AA, de Leeuw PW, Bozkurt O, Klungel OH. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci 2008; e-pub ahead of print 30 Nov 2008.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
11. Organization, WH. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO collaborating centre for Drug Statistics Methodology-Nordic Council on Medicines, 1999.
12. Knaapen AM, Ketelslegers HB, Gottschalk RW, Janssen RG, Paulussen AD, Smeets HJ, Godschalk RW, Van Schooten FJ, Kleinjans JC, Van Delft JH. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem 2004; 50:1664-1668.
13. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002; 20:2023-2027.
14. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58:1268-1278.
15. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol 1996; 144:207-213.
16. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352-358.
17. Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension 1983; 5: 36-42.
18. Weisser B, Ripka O. Long-term diuretic therapy: effects of dose reduction on antihypertensive efficacy and counterregulatory systems. J Cardiovasc Pharmacol1992; 19:361-366.
19. Ernsberger P, Koletsky RJ. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol 2006; 373:245-258.
20. White WB. Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update. J Clin Hypertens (Greenwich) 2007; 9:876-882.
21. Duncan JA, Scholey JW, Miller JA. Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr Opin Nephrol Hypertens 2001; 10:111-116.
22. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein B3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37:739-743.
23. Vormfelde SV, Sehrt D, Bolte D, Pahl S, Tzvetkov M, Brockmöller J. Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. Eur J Clin Pharmacol 2006; 62:195-201.
24. Mitchell A, Rushentsova U, Siffert W, Philipp T, Wenzel RR. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of G-protein B3 subunit (GNB3) C825T polymorphism. Clin Pharmacol Ther 2006; 79:274-281.
25. Shafi T, Appel LJ, Miller ER III, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52:1022-1029.